Brokers Offer Predictions for EBS Q1 Earnings

Emergent BioSolutions Inc. (NYSE:EBS) – Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for Emergent BioSolutions in a research note issued on Friday, March 21st. HC Wainwright analyst R. Selvaraju expects that the biopharmaceutical company will post earnings per share of $0.87 for the quarter. HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Emergent BioSolutions’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Emergent BioSolutions’ Q2 2026 earnings at $1.04 EPS, Q3 2026 earnings at $1.11 EPS and Q4 2026 earnings at $0.81 EPS.

Separately, StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th.

Emergent BioSolutions Stock Performance

Shares of EBS stock opened at $5.74 on Monday. The stock has a market capitalization of $311.62 million, a PE ratio of -1.40 and a beta of 1.80. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The business’s 50 day simple moving average is $8.41 and its 200 day simple moving average is $8.72. Emergent BioSolutions has a one year low of $1.82 and a one year high of $15.10.

Emergent BioSolutions (NYSE:EBS) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.40. The company had revenue of $194.70 million for the quarter, compared to analysts’ expectations of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same period last year, the firm earned ($0.77) earnings per share.

Insider Buying and Selling

In related news, Director Neal Franklin Fowler sold 35,000 shares of the company’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total transaction of $204,050.00. Following the completion of the transaction, the director now owns 101,100 shares in the company, valued at approximately $589,413. This represents a 25.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Emergent BioSolutions

Several hedge funds and other institutional investors have recently made changes to their positions in EBS. State Street Corp boosted its holdings in shares of Emergent BioSolutions by 864.7% in the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock valued at $15,960,000 after buying an additional 1,713,200 shares in the last quarter. Oak Hill Advisors LP acquired a new stake in shares of Emergent BioSolutions in the third quarter worth approximately $9,296,000. Millennium Management LLC boosted its holdings in shares of Emergent BioSolutions by 83.0% during the 4th quarter. Millennium Management LLC now owns 1,481,906 shares of the biopharmaceutical company’s stock worth $14,167,000 after purchasing an additional 671,947 shares during the last quarter. Invesco Ltd. increased its position in Emergent BioSolutions by 70.9% during the fourth quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company’s stock worth $14,722,000 after purchasing an additional 638,995 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Emergent BioSolutions by 67.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company’s stock worth $10,554,000 after purchasing an additional 444,790 shares during the period. Hedge funds and other institutional investors own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.